References
- Vardiman JW, Arber D, Brunning R, . Therapy-related myeloid neoplasms. In: Swerdlow S, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press; 2008, pp 127–129.
- Singh ZN, Huo D, Anastasi J, . Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007;127:197–205.
- Buchner T, Berdel WE, Haferlach C, . Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61–69.
- Grimwade D, Hills RK, Moorman AV, . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.
- Schnittger S, Schoch C, Kern W, . Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733–3739.
- Thiede C, Koch S, Creutzig E, . Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011–4020.
- Bains A, Luthra R, Medeiros LJ, . FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011;135:62–69.
- Schnittger S, Schoch C, Dugas M, . Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59–66.
- Kayser S, Dohner K, Krauter J, . The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137–2145.